"’Azienda ospedaliera per l’emergenza "Cannizzaro" di Catania è Azienda di Riferimento regionale per l’emergenza-urgenza ed è sede di strutture di alta specializzazione. L'Azienda è anche pronto soccorso e garantisce servizi essenziali di emergenza - urgenza Azienda Ospedaliera per l'Emergenza Cannizzaro Via Messina, 829 - 95126 CATANIA"

During the past decade, Azienda Ospedaliera Cannizzaro conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 9 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 9 clinical trials were completed. i.e. 69.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera Cannizzaro" #1 sponsor was "Takeda" with 4 trials, followed by "Merck Sharp & Dohme LLC" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "University of Catania" with 3 trials sponsored and "Abbott Medical Devices" with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera Cannizzaro" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Agenzia Italiana del Farmaco" with 2 trials as a collaborator, "Azienda Sanitaria-Universitaria Integrata di Udine" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Belgian Gynaecological Oncology Group" with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera Cannizzaro" are "Ulcerative Colitis" (4 trials), "Crohn's Disease" (3 trials), "Prostatic Neoplasms" (3 trials), "COVID-19" (2 trials) and "Colitis, Ulcerative" (2 trials). Many other conditions were trialed in "Azienda Ospedaliera Cannizzaro" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera Cannizzaro" are "Drug" (29 trials), "Other" (5 trials), "Biological" (4 trials), "Device" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Pembrolizumab" (5 trials), "Carboplatin" (3 trials), "Etrasimod" (3 trials) and "placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera Cannizzaro" are 25 trials for "All" genders, 8 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera Cannizzaro". undefined are not yet recruiting, 5 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Azienda Ospedaliera Cannizzaro, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera Cannizzaro, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".

Azienda Ospedaliera Cannizzaro has several departments that took part in Clinical trials: "Ospedale Cannizzaro, Divisione di Ostetricia e Ginecologia" - 2 trials